ES2152929T3 - Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes. - Google Patents

Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes.

Info

Publication number
ES2152929T3
ES2152929T3 ES92915347T ES92915347T ES2152929T3 ES 2152929 T3 ES2152929 T3 ES 2152929T3 ES 92915347 T ES92915347 T ES 92915347T ES 92915347 T ES92915347 T ES 92915347T ES 2152929 T3 ES2152929 T3 ES 2152929T3
Authority
ES
Spain
Prior art keywords
deaminase
citosine
techniques
selection system
negative selection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92915347T
Other languages
English (en)
Inventor
Craig A Mullen
R Michael Blaese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2152929T3 publication Critical patent/ES2152929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Devices For Checking Fares Or Tickets At Control Points (AREA)
  • Brushes (AREA)
  • Exchange Systems With Centralized Control (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UN SISTEMA QUE COMPRENDE UN GEN BACTERIANO MODIFICADO DE DEAMINASA DE CITOSINA QUE HA SIDO MANIPULADO PARA CONSEGUIR UN VECTOR DE EXPRESION EUCARIOTICA Y LA EXPRESION DEL GEN MEDIANTE FIBROBLASTOS DE MURINA. LA INVENCION SE REFIERE ADEMAS A LOS METODOS, TERAPIAS DE GENES Y VACUNAS QUE EMPLEAN EL MARCADOR SELECCIONABLE NEGATIVO, LA DEAMINASA DE CITOSINA, QUE TIENE LA CAPACIDAD DE PRODUCIR 5-FLUOROURACIL TOXICO, ANTIMETABOLITO A PARTIR DE 5-FLUOROCITOSINA.
ES92915347T 1991-07-03 1992-06-30 Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes. Expired - Lifetime ES2152929T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/725,076 US5358866A (en) 1991-07-03 1991-07-03 Cytosine deaminase negative selection system for gene transfer techniques and therapies

Publications (1)

Publication Number Publication Date
ES2152929T3 true ES2152929T3 (es) 2001-02-16

Family

ID=24913069

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92915347T Expired - Lifetime ES2152929T3 (es) 1991-07-03 1992-06-30 Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes.

Country Status (12)

Country Link
US (2) US5358866A (es)
EP (1) EP0595873B1 (es)
JP (1) JP3386461B2 (es)
AT (1) ATE191505T1 (es)
AU (1) AU667820B2 (es)
CA (1) CA2112395C (es)
DE (1) DE69230882T2 (es)
DK (1) DK0595873T3 (es)
ES (1) ES2152929T3 (es)
GR (1) GR3033909T3 (es)
SG (1) SG52475A1 (es)
WO (1) WO1993001281A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2042093C (en) * 1990-05-09 2002-12-24 Gyula Hadlaczky Cell line carrying an excess of mammalian centromeres
US6555370B1 (en) * 1990-11-13 2003-04-29 Immunex Corporation Bifunctional selectable fusion genes
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2683725B1 (fr) * 1991-11-15 1995-07-07 Pasteur Institut Composition cellulaire pour le traitement des organismes humains ou animaux.
CA2134763A1 (en) * 1992-05-01 1993-11-11 Kenneth W. Culver Bystander effect tumoricidal therapy
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
DE69524740T2 (de) * 1994-05-02 2002-08-14 Univ Washington Seattle Thymidin-kinase-mutanten
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
US6013517A (en) * 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
US5856153A (en) * 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
AU7525496A (en) * 1995-10-23 1997-05-15 Betagene, Inc. Methods and compositions comprising glut-2 and glut-2 chimeras
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
US6025155A (en) * 1996-04-10 2000-02-15 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20020160970A1 (en) * 1996-04-10 2002-10-31 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6077697A (en) * 1996-04-10 2000-06-20 Chromos Molecular Systems, Inc. Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US20030033617A1 (en) * 1996-04-10 2003-02-13 Gyula Hadlaczky Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
JP2002504340A (ja) 1998-02-19 2002-02-12 セイント．ジュード チルドレンズ リサーチ ホスピタル ヒト腫瘍細胞類を感作しおよびヒト腫瘍細胞の増殖を阻害するための組成物および方法
GB9810752D0 (en) * 1998-05-19 1998-07-15 Glaxo Group Ltd Cystosine deaminase gene
US20020115213A1 (en) * 1998-08-14 2002-08-22 Northeastern Ohio Universities Of Medicine Engraftable neural progenitor & stem cells for brain tumor therapy
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
US7186409B2 (en) 1998-08-14 2007-03-06 The Children's Medical Center Corporation Neural stem cells and use thereof for brain tumor therapy
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
US8716558B2 (en) 1999-06-30 2014-05-06 Marker Gene Technologies, Inc. Method of altering glycosylation of proteins in response to nojirimycin glucuronide in a plant cell expressing glucuronidase
US6656917B1 (en) * 1999-06-30 2003-12-02 Marker Gene Technologies, Inc. Compositions and methods for targeted enzymatic release of cell regulatory compounds
AU2001247442B2 (en) * 2000-03-15 2006-07-27 Children's Medical Center Corporation Systemic gene delivery vehicles for the treatment of tumors
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
PT1911837E (pt) * 2000-09-28 2011-06-07 Bioriginal Food & Science Corp Membro da família de desaturases dos ácidos gordos fad5-2 e suas utilizações
EP1264891A1 (en) * 2001-05-31 2002-12-11 Plant Research International B.V. Modification of plant genomes by inducible site-specific recombination of transgenes
EP1430140B1 (en) * 2001-08-01 2010-09-15 University of Utah N-terminally truncated isoforms of pde3a cyclic phosphodiesterases
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP1527183B1 (de) * 2002-07-26 2008-08-20 BASF Plant Science GmbH Neue selektionsverfahren
US20040149174A1 (en) * 2003-02-05 2004-08-05 Mbt Holding Ag Accelerating admixture for concrete
ATE497974T1 (de) 2003-07-21 2011-02-15 Transgene Sa Multifunktionelle cytokine
US7790445B2 (en) 2003-07-21 2010-09-07 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
JP2007511507A (ja) * 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
ATE546536T1 (de) * 2004-03-17 2012-03-15 Basf Plant Science Gmbh Verbessertes konstrukt für marker ausschneiden gestützt auf einen doppelfunktion selektionsmarker
US20080039328A1 (en) * 2004-03-17 2008-02-14 Basf Plant Science Gmbh Post Harvest Control of Genetically Modified Crop Growth Employing D-Amino Acid Compounds
US7510868B2 (en) 2004-05-26 2009-03-31 Paul Harden Chimeric adenoviruses for use in cancer treatment
EP2166103B1 (en) 2004-08-02 2013-05-22 BASF Plant Science GmbH Method for isolation of transcription termination sequences
US8034994B2 (en) 2005-04-19 2011-10-11 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
US20070026012A1 (en) 2005-08-01 2007-02-01 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
AU2006283130B2 (en) 2005-08-22 2012-02-09 Cornell Research Foundation, Inc. Compositions and methods for analyzing protein interactions
EP2074219B1 (en) 2007-02-16 2013-11-20 BASF Plant Science GmbH Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US20090196854A1 (en) * 2008-02-04 2009-08-06 Kytos Biosystems S.A. Methods and compositions for use of crl 5803 cells for expression of biotherapeutics and encapsulated cell-based delivery
KR101870056B1 (ko) 2008-09-26 2018-07-23 토카겐 인크. 유전자 요법 벡터와 시토신 디아미나아제
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
RU2616870C1 (ru) * 2011-12-21 2017-04-18 СиДжей ЧеилДжеданг Корпорейшн Способ получения L-лизина с использованием микроорганизмов, обладающих способностью продуцировать L-лизин
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
PL3021859T3 (pl) 2013-10-25 2018-06-29 Psioxus Therapeutics Limited Adenowirusy onkolityczne wyposażone w geny heterolityczne
EP3082834B1 (en) 2013-12-11 2020-03-11 The General Hospital Corporation DBA Massachusetts Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
CA2943871A1 (en) 2014-04-10 2015-10-15 Transgene S.A. Poxviral oncolytic vectors
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
SI3288573T1 (sl) 2015-04-30 2020-06-30 Psioxus Therapeutics Limited Onkolitični adenovirus, ki kodira protein B7
CN108697746A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的病毒
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
KR102371151B1 (ko) 2020-03-13 2022-03-07 주식회사 큐로셀 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
CA2018273C (en) * 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
GB8919607D0 (en) * 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies

Also Published As

Publication number Publication date
JPH07501925A (ja) 1995-03-02
SG52475A1 (en) 1998-09-28
JP3386461B2 (ja) 2003-03-17
WO1993001281A1 (en) 1993-01-21
EP0595873B1 (en) 2000-04-05
EP0595873A1 (en) 1994-05-11
DK0595873T3 (da) 2000-07-10
EP0595873A4 (en) 1994-12-07
US5624830A (en) 1997-04-29
DE69230882D1 (de) 2000-05-11
CA2112395A1 (en) 1993-01-21
DE69230882T2 (de) 2000-11-09
US5358866A (en) 1994-10-25
CA2112395C (en) 2008-04-22
AU667820B2 (en) 1996-04-18
ATE191505T1 (de) 2000-04-15
AU2295992A (en) 1993-02-11
GR3033909T3 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
ES2152929T3 (es) Sistema de seleccion negativa de la deaminasa de citosina para terapias y tecnicas de transferencia de genes.
Suenaga et al. Engineering large viral DNA genomes using the CRISPR‐Cas9 system
DK0500917T3 (da) Vacciner og fremgangsmåder baseret på rekombinante herpes simplex virusser.
Simard The nucleus: action of chemical and physical agents
ES2121794T3 (es) Procedimiento de transferencia de genes por medio de retrotransposones.
DE60303810D1 (de) Kontrollierte bakterielle lyse zur verabreichung von dna vakzinvektoren und impfantigen
EP0846160A4 (en) METHODS TO INCREASE THE PRODUCTION OF VIRAL VACCINE IN CELL CULTURE BY SUPPRESSING INTERFERON
HK1018287A1 (en) (-)-strand rna virus vector having autonomously replicating activity
ATE270342T1 (de) Endosomolytisch wirksame partikel
Cohen et al. Potential biohazards of recombinant DNA molecules
Markus et al. Optimizing systems for Cas9 expression in Toxoplasma gondii
Bodmer et al. Uptake and incorporation of thymine, thymidine, uracil, uridine, and 5-fluorouracil into the nucleic acids of Bacillus subtilis
Lieberman et al. Avoiding the kiss of death: how HIV and other chronic viruses survive
CN108048483A (zh) 复制型重组腺病毒HAdV-5载体系统及其应用
DE69033961D1 (de) Zellinien, die einen biologisch aktiven faktor-ix exprimieren
DE60016429D1 (de) Zell- und/oder tumor-spezifische promotor-abhängige änderung der gezielten expression des herpes gamma 34.5 gens
Doersen et al. Cytoplasmic inheritance of erythromycin resistance in human cells.
Dulbecco Transformation of cells in vitro by DNA-containing viruses
Evans et al. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers
Welsh et al. Lymphocyte-dependent ‘natural’immunity to virus infections mediated by both natural killer cells and memory T cells
Mullen et al. Cytosine deaminase negative selection system for gene transfer techniques and therapies
Tolmachov Swarm intelligence in cell entry exclusion phenomena in viruses and plasmids: how to exploit intelligent gene vector self-scattering in therapeutic gene delivery
GB9506298D0 (en) Diagnostic system
Xing et al. An Improved Genome Engineering Method Using Surrogate Reporter-Coupled Suicidal ZFNs
Jason et al. Modeling and analysis of gene-therapeutic combination chemotherapy for pancreatic cancer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 595873

Country of ref document: ES